Clinical Trials
27 trialsThe CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
American Society of Clinical Oncology
TAPUR
American Society of Clinical Oncology
Palbociclib and Pembrolizumab in Sarcoma
University of Iowa
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Memorial Sloan Kettering Cancer Center
PALAVY
Abramson Cancer Center at Penn Medicine
PAveMenT
Royal Marsden NHS Foundation Trust
SPARCC
Dana-Farber Cancer Institute
Palbociclib and Pembrolizumab In Central Nervous System Metastases
Massachusetts General Hospital
Tazemetostat and Palbociclib With CPX-351for R/R AML
Thomas Jefferson University
Combined Immunotherapies in Metastatic ER+ Breast Cancer
Weill Medical College of Cornell University
A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
West China Hospital
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Northwestern University
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
UNC Lineberger Comprehensive Cancer Center
APEAK
Sun Yat-sen University
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Pilot Trial for Treatment of Recurrent Glioblastoma
AHS Cancer Control Alberta
COPS-01
Rabin Medical Center
Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)
Tianjin Medical University Second Hospital
A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
Fudan University
PLATFORM Study of Precision Medicine for Rare Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
PALMARES-2
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Tianjin Medical University Second Hospital
TRAK-ER
Royal Marsden NHS Foundation Trust
PTST_PALBEVA
Lebanese University
DRUP
The Netherlands Cancer Institute
ORACLE-RIPA
National Taiwan University Hospital
EVIDENT
Oslo University Hospital